QLS-111 / Qlaris Bio - LARVOL DELTA

QC-111-202: Study of an Investigational Product, QLS-111, Provided as an Eyedrop, for Treatment of Normal Tension Glaucoma (NTG) (clinicaltrials.gov) - P2 | N=36 | Recruiting | Sponsor: Qlaris Bio, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Glaucoma • Ophthalmology

Safety, tolerability and ocular hypotensive properties of QLS-111, a novel formulation of an ATP sensitive potassium channel opener, alone or in combination with approved ocular hypotensive drugs (ARVO 2025) - "These findings highlight the potential of QLS-111 as a strong and well-tolerated therapeutic option for better management of intraocular pressure in diseases like glaucoma. Clinical trials are currently underway to explore the benefits of QLS-111, either alone or in combination with latanoprost, in patients with glaucoma or elevated eye pressure."

Clinical • Combination therapy • Glaucoma • Ophthalmology

QC-111-202: Study of an Investigational Product, QLS-111, Provided As an Eyedrop, for Treatment of Normal Tension Glaucoma (NTG) (clinicaltrials.gov) - P2 | N=36 | Not yet recruiting | Sponsor: Qlaris Bio, Inc. | N=60 ➔ 36

Enrollment change • Glaucoma • Ophthalmology

Qlaris Bio Announces Positive Topline Data From…Phase II Trials of QLS-111 in Patients With Primary Open Angle Glaucoma and Ocular Hypertension (Businesswire) - P2 | N=36 | Apteryx (NCT06249152) | Sponsor: Qlaris Bio, Inc. | "The Phase II trials...successfully met all primary and secondary endpoints...The Apteryx study...QLS-111 0.015% dosed with latanoprost drove additive mean IOP reductions as compared to latanoprost monotherapy, achieving a 3.2 mmHg greater reduction for QLS-111 QPM dosing and 3.6 mmHg greater reduction for QLS-111 BID (twice daily) dosing."

P2 data • Glaucoma • Ophthalmology

Qlaris Bio Announces Positive Topline Data From…Phase II Trials of QLS-111 in Patients With Primary Open Angle Glaucoma and Ocular Hypertension (Businesswire) - P2 | N=63 | Osprey (NCT06016972) | Sponsor: Qlaris Bio, Inc. | "The Phase II trials...successfully met all primary and secondary endpoints. Qlaris Bio will present a corporate update at the Glaucoma 360 New Horizons Forum 2025 on February 7th in San Francisco, CA. The Osprey study...demonstrated that the 0.015% concentration of QLS-111 dosed QPM (once daily in the evening) drove the greatest decrease in IOP, highlighted by mean reductions of 3.7 mmHg from mean diurnal baseline IOP of 23.0 mmHg."

P2 data • Glaucoma • Ophthalmology

QC-111-203: Qlaris Study of QLS-111 in Combination With a PGA for OAG and/or OHT Patients (clinicaltrials.gov) - P2 | N=36 | Completed | Sponsor: Qlaris Bio, Inc. | Recruiting ➔ Completed

Trial completion • Cardiovascular • Glaucoma • Ophthalmology

Qlaris Phase 2 Study of QLS-111 in POAG And/or OHT Patients (clinicaltrials.gov) - P2 | N=63 | Completed | Sponsor: Qlaris Bio, Inc. | Active, not recruiting ➔ Completed

Trial completion • Cardiovascular • Glaucoma • Ophthalmology

Qlaris Phase 2 Study in NTG Patients (clinicaltrials.gov) - P2 | N=60 | Not yet recruiting | Sponsor: Qlaris Bio, Inc. | Trial completion date: Apr 2025 ➔ Oct 2025 | Trial primary completion date: Mar 2025 ➔ Oct 2025

Trial completion date • Trial primary completion date • Glaucoma • Ophthalmology

Qlaris Phase 2 Study in NTG Patients (clinicaltrials.gov) - P2 | N=60 | Not yet recruiting | Sponsor: Qlaris Bio, Inc. | N=120 ➔ 60

Enrollment change • Glaucoma • Ophthalmology

Qlaris Phase 2 Study of QLS-111 in POAG and/or OHT Patients (clinicaltrials.gov) - P2 | N=60 | Active, not recruiting | Sponsor: Qlaris Bio, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Cardiovascular • Glaucoma • Ophthalmology

QC-111-203: Qlaris Study of QLS-111 in Combination With a PGA for OAG and/or OHT Patients (clinicaltrials.gov) - P2 | N=48 | Recruiting | Sponsor: Qlaris Bio, Inc. | Not yet recruiting ➔ Recruiting

Combination therapy • Enrollment open • Cardiovascular • Glaucoma • Ophthalmology

Qlaris Phase 2 Study of QLS-111 in POAG and/or OHT Patients (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: Qlaris Bio, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Glaucoma • Ophthalmology

Qlaris Study of QLS-111 in Combination With a PGA for OAG and/or OHT Patients (clinicaltrials.gov) - P2 | N=48 | Not yet recruiting | Sponsor: Qlaris Bio, Inc.

Combination therapy • New P2 trial • Cardiovascular • Glaucoma • Ophthalmology

Qlaris Phase 2 Study of QLS-111 in POAG and/or OHT Patients (clinicaltrials.gov) - P2 | N=60 | Not yet recruiting | Sponsor: Qlaris Bio, Inc. | N=120 ➔ 60 | Trial completion date: Dec 2024 ➔ Sep 2024

Enrollment change • Trial completion date • Cardiovascular • Glaucoma • Ophthalmology

Qlaris Phase 2 Study in NTG Patients (clinicaltrials.gov) - P2 | N=120 | Not yet recruiting | Sponsor: Qlaris Bio, Inc. | Initiation date: Feb 2024 ➔ May 2024

Trial initiation date • Glaucoma • Ophthalmology

Qlaris Phase 2 Study in NTG Patients (clinicaltrials.gov) - P2 | N=120 | Not yet recruiting | Sponsor: Qlaris Bio, Inc.

New P2 trial • Glaucoma • Ophthalmology

Qlaris Phase 2 Study of QLS-111 in POAG and/or OHT Patients (clinicaltrials.gov) - P2 | N=120 | Not yet recruiting | Sponsor: Qlaris Bio, Inc.

New P2 trial • Cardiovascular • Glaucoma • Ophthalmology